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ORIGINAL ARTICLE
WNT/β-catenin signaling regulates mitochondrial activity to
alter the oncogenic potential of melanoma in a PTEN-
dependent manner
K Brown1,6, P Yang2, D Salvador3, R Kulikauskas2, H Ruohola-Baker4, AM Robitaille2, AJ Chien2,5, RT Moon2 and V Sherwood1,3
Aberrant regulation of WNT/β-catenin signaling has a crucial role in the onset and progression of cancers, where the effects are not
always predictable depending on tumor context. In melanoma, for example, models of the disease predict differing effects of the
WNT/β-catenin pathway on metastatic progression. Understanding the processes that underpin the highly context-dependent
nature of WNT/β-catenin signaling in tumors is essential to achieve maximal therapeutic beneﬁt from WNT inhibitory compounds.
In this study, we have found that expression of the tumor suppressor, phosphatase and tensin homolog deleted on chromosome 10
(PTEN), alters the invasive potential of melanoma cells in response to WNT/β-catenin signaling, correlating with differing metabolic
proﬁles. This alters the bioenergetic potential and mitochondrial activity of melanoma cells, triggered through regulation of pro-
survival autophagy. Thus, WNT/β-catenin signaling is a regulator of catabolic processes in cancer cells, which varies depending on
the metabolic requirements of tumors.
Oncogene advance online publication, 16 January 2017; doi:10.1038/onc.2016.450
INTRODUCTION
The importance of WNT signaling in metazoans cannot be
underestimated; the pathways are essential in embryonic devel-
opment, coordinating correct tissue patterning and for home-
ostasis in adult tissues. As such, aberrant WNT signaling can lead
to a host of embryonic malformations, degenerative diseases and
cancer. Thus, understanding how WNT signaling affects cells and
tissues has far reaching implications in animal biology. WNT
proteins comprise a large family of secreted glycoproteins
(19 members in vertebrates) that modulate a number of signal
transduction pathways in a highly tissue context-dependent
manner.1 The pathways can be subdivided into two categories
based on their capacity to transduce signals via the pleiotropic
protein, β-catenin (encoded by the CTNNB1 gene), and are
therefore referred to as either eliciting β-catenin-dependent or
-independent signaling (sometimes also referred to as canonical
or non-canonical WNT signaling, respectively). However, the
pathways do not function in an autonomous manner, but rather
exist in a signaling network where there is concomitant cross-talk
and regulation between the β-catenin-dependent, and -indepen-
dent pathways.2 The WNT/β-catenin pathway results in the
stabilization of a cytoplasmic pool of β-catenin that would
otherwise be marked for proteasomal-mediated degradation by
a destruction complex, composed of (among other proteins) APC
(encoded by APC), AXIN-1/2 (encoded by AXIN1/2) and GSK-3β
(encoded by GSK3B). Upon binding to receptors of the Frizzled
(FZD) family and the co-receptors, LRP5/6, extracellular WNT
stimulation transmits a signal to the intracellular Disheveled (DVL)
adaptor, which inhibits the destruction complex and allows
nuclear translocation of stabilized β-catenin to activate gene
transcription. In the nucleus, β-catenin acts as a cofactor with
transcription factor/lymphoid enhancer-binding element tran-
scription factors to stimulate expression of WNT target genes
such as AXIN2 and MYC.3–5
Since the 1980s researchers have known that the WNT
pathways have an inﬂuential role in carcinogenesis, after WNT1
was shown to induce the formation of mammary tumors in
mice.6–8 The WNT signaling network is now known to regulate
oncogenesis in a diverse array of cancers including (in addition to
breast), tumors derived from the blood, gastro-intestinal tract,
brain, prostate, ovaries, liver and skin, to name a few. Traditionally,
the WNT/β-catenin pathway has been viewed as oncogenic,
where hyperactivity of the pathway promotes carcinogenesis. For
example, in colorectal cancer loss-of-function mutations in APC
can be detected in up to 80% of tumors,9,10 leading to increased
β-catenin signaling and prompting researchers to develop
inhibitory compounds for the pathway.11 However, it is not that
simple in all tumor contexts, as high levels of nuclear β-catenin
does not always correlate with poor prognosis for all tumor types,
including medulloblastoma,12 ovarian cancer,13 prostate cancer14
and melanoma.15
Melanoma is a malignancy derived from the pigment-producing
cells, melanocytes, and alarmingly has some of the fastest growing
incidence rates among human cancers worldwide.16,17 WNT/β-
catenin signaling in melanoma tumors has previously been shown
to correlate with improved survival in patients, which was
corroborated by murine xenograft models where melanoma cells
overexpressing WNT3A exhibit reduced tumor volumes and
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Figure 1. Melanoma cells exhibit increased apoptosis in response to WNT/β-catenin signaling. (a) Panel of chosen melanoma cells describing
their associated genetic backgrounds for BRAF, NRAS and PTEN status. (b) Hetero- and homozygous mutations in the PTEN gene, result in
depleted PTEN and phosphorylated-AKT (P-Akt) expression. In all, 10 μg of whole-cell lysate of PTENWT and PTENMut lines were blotted for
PTEN, AKT and P-AKT (t308) expression. α-Tubulin served as the loading control. (c) Ratio of the protein expression of AKT relative to P-AKT in
individual melanoma cells and the average ratio of PTENWT and PTENMut cell lines. Calculated from data presented in b. (d) WNT3A induces
β-catenin-transcription factor/lymphoid enhancer-binding element reporter activity in melanoma cells. Results were normalized to the
inverted promoter reporter plasmid (FOPFlash) after 24 h stimulation with carrier or rWNT3A (50 ng/ml). (e) Western blot analysis of WNT3A
expression levels in A375 and A2058 control and WNT3A overexpression cells. Heat shock protein 90 (Hsp90) served as a loading control. (f)
Stable overexpression of WNT3A in melanoma cells induces WNT/β-catenin signaling as measured using the TOPFlash β-catenin-transcription
factor/lymphoid enhancer-binding element reporter. Results normalized to FOPFlash after 24 h of serum starvation. (g) Stable WNT3A
overexpression reduces melanoma cell numbers. Live population cell counts of A375 and A2058 control, and WNT3A overexpression cells
were carried out over 36 and 21 days, respectively. A paired Student’s t-test was carried out on the total cell number, as indicated (*). (h)
WNT3A increases apoptosis in melanoma cells. Fold-change in Apo-TRACE staining following 48 h serum starvation in A375 and A2058
control, and WNT3A overexpression cells. Fluorescence was normalized to total protein concentration. For all panels, mean± s.d. *Po0.05 or
**Po0.01.
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metastasis compared with parental cells.15 Furthermore, reduced
β-catenin expression has been associated with progression of
melanoma in additional clinical cohorts.18–21 However, other
experimental work challenges the assumption that increased
WNT/β-catenin signaling reduces the growth and spread of
melanocytic tumors. Engineered murine models of melanoma
that express melanocyte-speciﬁc phosphatase and tensin homo-
log deleted on chromosome 10 (PTEN) loss and the constitutively
activating BRAFV600E mutation (two mutations commonly asso-
ciated with melanocytic tumors in patients), exhibit highly
metastatic and aggressive tumors when β-catenin is stabilized.22
These observations suggest that subsets of melanoma tumors
containing distinct mutational contexts, respond to stabilized
β-catenin with potentially differing effects on disease progression,
highlighting the need to better understand the role of the WNT/β-
catenin pathway in melanoma cell behavior.
Interest in the topic of cancer metabolism has been revived in
recent years as accumulating evidence has demonstrated the
contribution that these metabolic alterations have on the
establishment and progression of tumors.23 Indeed, metabolic
reprogramming is a hallmark of cancer,24 which has been
demonstrated in a number of tumor types to be regulated by
WNT signaling (as we have recently reviewed, Sherwood25),
including in melanoma.26 We have previously shown that WNT5A
(signaling in a β-catenin-independent manner) promotes aerobic
glycolysis in melanoma cells,26 which may contribute to the pro-
metastatic effects of this signaling pathway in melanoma.
Furthermore, the WNT/β-catenin pathway has also been shown
to promote aerobic glycolysis in colorectal cancer and promote
cell proliferation.27 Currently it is unknown if WNT/β-catenin
signaling can also reprogram melanoma cell metabolism and if so,
what effect this may have on tumorigenic state.
Here we compare melanomas expressing wild-type PTEN
(PTENWT) with those expressing genetic deletions in this tumor
suppressor and analyze the phenotypic effects of the WNT/β-
catenin pathway in both subsets. We demonstrate that the WNT/
β-catenin pathway has profound effects on melanoma cell
invasion, metastasis and metabolic status between tumor cells
depending on PTEN expression status. Moreover we provide
evidence that in melanoma cells expressing PTEN, alterations in
cellular metabolism are associated with the control of mitochon-
drial activity and remodeling. Taken together, these results
support a model whereby WNT/β-catenin signaling controls
subsets of melanoma cells based on PTEN expression status,
which regulates metabolic behavior in the cells to alter their
invasive potential.
RESULTS
WNT3A increases apoptosis in melanoma cells
Driver mutations that result in hyper-activation of the mitogen-
activated protein kinase pathway exist in the majority of
melanoma tumors and occur predominantly through activating
mutations of either BRAF (approximately 50%) or NRAS (approxi-
mately 20%),28–30 which tend to be mutually exclusive.31 Although
less prevalent than mitogen-activated protein kinase pathway
alterations, loss of PTEN (the lipid and protein phosphatase that
negatively regulates the phosphatidylinositol-3-kinase (PI3K)-AKT
pathway) through deletion, mutation or reduced expression,
occurs in approximately 5–40% of melanocytic tumors.31–33 We
selected a panel of cell lines with known status of these common
mutations in melanoma (Figure 1a) to investigate the context-
dependent nature of WNT/β-catenin signaling in melanocytic
tumors. Half of the lines had PTENWT expression, whereas the
other 50% had homo- or heterozygous deletions in PTEN
(PTENMut; Figure 1a). The PTENMut cells were conﬁrmed to have
reduced expression of PTEN compared with the PTENWT lines
(Figure 1b) and higher levels of phosphorylated-AKT (P-AKT) on
Thr308, showing that PI3K signaling is activated in the PTENMut
lines (Figures 1b and c).
WNT3A has been previously shown to signal through β-catenin
in human melanoma cells.15 To conﬁrm this ﬁnding in our
melanoma panel, we ensured that recombinant WNT3A (rWNT3A)
could activate a β-catenin-responsive reporter in the cells
(Figure 1d). Furthermore, constitutive overexpression of WNT3A
using a WNT3A-iresGFP reporter construct in two of the lines (one
PTENWT line, A375; and one PTENMut line, A2058; Figure 1e) also
led to enhanced signaling from this reporter construct (Figure 1f),
demonstrating that WNT3A activates β-catenin signaling the
selected melanoma panel.
It is well known that the WNT/β-catenin pathway is associated
with deregulated cell proliferation and neoplasia through multiple
mechanisms including cell cycle control, regulation of apoptosis
and mitotic control, as previously reviewed.34 To investigate the
role of the WNT/β-catenin pathway in melanoma cells, we ﬁrst
analyzed long-term cell proliferation in response to forced WNT3A
signaling. By monitoring population doublings over several weeks,
we found that hyperactive WNT3A signaling resulted in reduced
cell counts (Figure 1g), which is comparable with previous
ﬁndings.15 Analysis of cell division showed no signiﬁcant
difference in G0/G1, S and G2/M phases of the cell cycle in
response to overexpressed WNT3A in the melanoma cells
(Supplementary Figure 1a), demonstrating that the differences in
cell numbers during long-term proliferation assays identiﬁed in
Figure 1g were not due to cell cycle arrest. The cell cycle analysis
did, however, show a marked shift in the SubG1 population in
response to WNT3A (Supplementary Figure 1a), suggesting there
may be an accumulation of apoptotic cells. To conﬁrm this, we
analyzed the amount of cells committed to apoptosis through
annexin V staining and found that WNT3A-activated signaling
signiﬁcantly increased apoptosis in melanoma cells (Figure 1h).
This observation was further supported by the ﬁnding that WNT3A
overexpression also led to a signiﬁcant increase in cytochrome c
release from the mitochondria to the cytosol (Supplementary
Figure 1b). Taken together, our data show that WNT/β-catenin
signaling increases apoptosis in melanoma cells (irrespective of
PTEN mutational status).
WNT3A regulates melanoma cell invasion in a PTEN-dependent
manner
In addition to the effects on tumor growth, WNT signaling
pathways are also regulators of cell motility, able to enhance or
inhibit the migratory capacity of cancer cells in a cell-type-speciﬁc
manner.35–41 Using the two WNT3A overexpression lines
(Figure 1e), we evaluated the cells’ ability to ﬁll a wound scratch
and found an inverse correlation in cell migration in response to
high WNT/β-catenin signaling between the two lines (Figure 2a
and Supplementary Figure 2a). Speciﬁcally, cell migration was
reduced by WNT3A signaling in the PTENWT A375 cells, whereas in
contrast, this effect was enhanced in the PTENMut A2058 cells
(Figure 2a and Supplementary Figure 2a). This result suggested
that WNT/β-catenin signaling may control melanoma cell motility
in a PTEN expression-dependent manner.
Interestingly it has previously been reported that in melanoma,
depending on the cell line used, β-catenin signaling can either
enhance or reduce cell invasion,18,42 therefore we investigated the
effects of WNT3A on the invasive capacity of our panel of
melanoma cells. WNT signaling has been linked to the metastatic
spread of melanoma cells by driving phenotype switching, a
process that forces the cells to switch between invasive and
proliferative states, which can be assessed by three-dimensional
(3D) culture of melanoma cells.43 Proliferative phenotypes form
round, individual colonies and invasive phenotypes form inter-
connected colonies.43 We were unable to switch the 3D
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phenotypes of a subset of our melanoma panel (two PTENWT and
two PTENMut lines) in response to rWNT3A stimulation (Figure 2b),
suggesting that activation of WNT/β-catenin signaling is
insufﬁcient to drive phenotype switching in 3D culture in the
selected panel. We did, however, ﬁnd that WNT3A signaling could
markedly alter the invasive properties of the melanoma cell panel
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in MatrigelTM, where PTENWT cells responded with signiﬁcantly
reduced invasive capacity and PTENMut lines with enhanced
invasion in response to WNT3A-activated signaling (Figure 2c and
Supplementary Figure 2b).
Our in vitro invasion ﬁndings are supportive of previously
described results from melanocyte-speciﬁc PTEN loss and BRAFV600E
mice, where stabilization or loss of β-catenin led to enhanced or
reduced melanoma metastasis, respectively.22 However, it is currently
unknown how WNT/β-catenin signaling can affect metastasis on a
PTENWT background. To address this question, we performed
intravenous injection of GFP-labeled, PTENWT WNT3A overexpression
cells and monitored metastatic tumor formation in lung tissue. We
found there was reduced tumor burden in the lungs of mice injected
with the WNT3A overexpression cells compared with control cells,
where distinct areas of metastatic-free tissue could be observed in
the WNT3A animals compared with control lungs (Figure 2d). To
conﬁrm these ﬁndings, we used S100 as a melanoma marker in the
lung tissue sections, to identify metastatic lesions (Supplementary
Figure 2c). Importantly, quantiﬁcation of the tumor burden in the
lungs was found to be signiﬁcantly reduced in the WNT3A
overexpression treated animals (Figure 2e).
To conﬁrm that these WNT/β-catenin-mediated effects on
melanoma cell motility are PTEN dependent, we overexpressed
PTEN in the mutant lines (A2058 and M229; Supplementary
Figure 2d) and found that re-establishment of PTEN expression
could the switch the effect of rWNT3A stimulation from pro- to
anti-migratory (Figure 2f and Supplementary Figure 2e). PTEN is
known to possess both PI3K-dependent and -independent
activities.44 To investigate if the WNT/β-catenin-mediated effects
on melanoma cell motility are PI3K dependent, we used the PI3K
inhibitor, LY294002, in PTENMut cells at a concentration that could
inhibit PI3K-AKT signaling (Figure 2g), but could not signiﬁcantly
alter basal cell migration (Figure 2h). LY294002 blocks WNT3A-
mediated increased cell migration in A2058 cells (Figure 2h),
demonstrating that the effect of WNT/β-catenin signaling on
melanoma cell motility is PI3K-dependent.
Using The Cancer Genome Atlas (TCGA) network cutaneous
melanoma data set, we identiﬁed 209 patient samples with high
AXIN2 transcript expression (based on RNA-seq transcriptome
analysis) as a marker of active WNT/β-catenin signaling and
divided the samples into two cohorts as PTEN low or high
expressing (n= 47 and n= 162, respectively; Supplementary Table
S1), based on ~ 20% of uncultured tumors expected to have
reduced PTEN expression.31,45,46 Analysis of the associated clinical
data (Supplementary Table S1) showed that total and lymph node
metastases in the PTEN high cohort is signiﬁcantly reduced
compared with PTEN low expressing tumors (Figure 2i). Distant
organ metastases were not signiﬁcantly different, albeit the
number of patients presenting these lesions was low in this
cohort (n= 11; Figure 2h and Supplementary Table S1). Impor-
tantly, AXIN2 low expressing patients (n= 127) for which PTEN
expression data were available, do not follow the same trend
when subdivided into PTEN high (n= 97) or low (n= 30) cohorts
(Supplementary Figure 2f and Supplementary Table S2), suggest-
ing that this effect on metastasis is not because of a change in
PTEN expression in isolation, but rather is speciﬁc to patients with
high WNT/β-catenin signaling. Taken together, these data show
that WNT/β-catenin signaling can reduce melanoma cell migra-
tion, invasion and metastasis in PTENWT cells, which is in contrast
to the effects observed in PTENMut cells.
WNT3A regulates the bioenergetics of melanoma cells in a PTEN-
dependent manner
Given the previously identiﬁed role of WNT signaling in regulating
cancer metabolism,25 we decided to investigate the bioenergetic
properties of PTENWT and PTENMut melanoma cells in response to
WNT3A signaling. To test this, we used a Seahorse XFe96 extracellular
ﬂux analyzer to investigate whether oxygen consumption rates (OCRs)
or extracellular acidiﬁcation rates (ECARs) were affected by WNT3A,
allowing us to study oxidative phosphorylation and indirectly also
glycolytic rates in the melanoma cells, respectively. Using the
overexpression melanoma cells, we found that both OCR and ECAR
rates were altered in response to WNT3A signaling, which interest-
ingly differed between the PTENWT and PTENMut lines (Supplementary
Figure 3). In A375 (PTENWT) cells, WNT3A overexpression led to
reduced rates of OCR and ECAR, which when analyzed for basic
parameters of cell respiratory control,47 showed signiﬁcantly reduced
rates of basal respiration, ATP production, maximal respiratory
capacity, non-mitochondrial respiration and basal ECAR (Figure 3a).
In the PTENMut A2058 cells, however, this reduction in cell respiratory
control upon WNT3A stimulation was not detected (Figure 3a and
Supplementary Figure 3). Overall, this represents a highly energetic to
quiescent metabolic shift in the A375 cells in response to WNT3A,
which is not observed in A2058 cells (Figure 3b).
To test whether the observations made using the XFe96 analyzer
were due to differences in the way PTENWT and PTENMut melanoma
cells respond bioenergetically to WNT3A signaling, we analyzed
metabolic responses to rWNT3A stimulation/WNT3A overexpression
in the whole panel of melanoma cells. First, we measured citrate
synthase (CS) activity, which is the initial enzyme of the tricarboxylic
acid cycle, to determine mitochondrial and oxidative phosphoryla-
tion activity in the cells. In all the PTENWT cell types tested, CS activity
was signiﬁcantly reduced in response to hyperactive WNT3A
signaling (Figure 3c). This was not reciprocated in all the in PTENMut
lines, which demonstrated unpredictable effects showing either
hyper- or hypo-activity of CS in response to WNT3A treatment
(Figure 3c). Next, we measured the glycolytic capacity of the
melanoma cells using secreted lactate as a marker. In response to
WNT3A, lactate secretion was signiﬁcantly reduced in all the PTENWT
lines tested (Figure 3d). Conversely this reduction was not observed
in any of the PTENMut cells when treated with rWNT3A (no signiﬁcant
Figure 2. PTENWT melanoma cells exhibit reduced motility and metastasis in response to WNT/β-catenin signaling. (a) Fold-change in cell
migration over 24 h in PTENWT and PTENMut control and WNT3A overexpression cells. Cells were grown to conﬂuency before the monolayer
was wounded and scratch size measured before, and after 24 h. (b) Representative images of 3D cell growth following 48 h stimulation with
carrier or 50 ng/ml rWNT3A. Arrows highlight connected cell clusters, which are indicative of invasive phenotypes in melanoma cells. Scale
bar, 200 μm. (c) Fold-change in cell invasion after 48 h compared with control cells. Parental lines were stimulated with carrier or 50 ng/ml
rWNT3A. For panels a and c, mean shown± s.d. *Po0.05, **Po0.01, ***Po0.001 and ****Po0.0001. (d) × 0.75 magniﬁcation images of
mouse lungs 4 weeks after tail vein injections of A375 control or WNT3A overexpression cells. Star highlights metastasis-free lung lobe.
Example images shown. (e) Quantitative scoring of S100 staining on mouse lung sections. Mean shown± s.d. ****Po0.0001. (f) Fold-change
in cell migration over 24 h in control and PTEN overexpressing A2058 and M229 cells, following 48 h stimulation with carrier or 50 ng/ml
rWNT3A. Cells were seeded to conﬂuency before the monolayer was wounded and scratch size measured before, and after 24 h. Mean
shown± s.d. *Po0.05, **Po0.01. (g) 2 μM of LY294002 inhibits AKT activity in PTENMut A2058 cell, after 48 h of stimulation. In total, 15 μg of
whole-cell lysate was blotted for AKT and P-AKT, following 48 h stimulation with carrier or 50 ng/ml rWNT3A. Ku80 served as the loading
control. (h) Fold-change in A2058 cell invasion after 48 h of treatment with 50 ng/ml rWNT3A/carrier with/without 2 μM LY294002, as indicated.
LY294002 was kept on the cells throughout the experiment. (i) Percentage of metastatic tumors in cutaneous melanoma patients (TCGA data
set) with high AXIN2 expression (n= 209). *Po0.05 or **Po0.01. Distant Mets, distant metastasis; Nodes, nodal metastasis.
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effect detected), however, stable overexpression of WNT3A led to
enhanced lactate secretion in these cells (Figure 3d). These data are
consistent with the ﬁndings of the XFe96 analyzer (Supplementary
Figure 3 and Figure 3a), showing that in response to enhanced
WNT3A signaling, PTENWT melanoma cells exhibit signiﬁcantly
reduced cellular metabolism, including both oxidative phosphoryla-
tion and glycolytic capacity. However, this is not the case for PTENMut
melanoma cells, which do not respond consistently to WNT3A-
mediated metabolic reprogramming. Taken together, these data
show that melanoma cells respond to WNT3A signaling with differing
metabolic signatures based on PTEN expression, which for the
PTENWT cells results in signiﬁcantly reduced cellular metabolism.
WNT3A remodels mitochondria in melanoma cells in
a PTEN-dependent manner
It is now known that adaptations of bioenergetic activity and
mitochondrial-derived ATP production, results in the remodeling
WNT/β-catenin and melanoma metastasis
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Figure 4. PTENWT melanoma cells exhibit increased mitochondrial networking in response to WNT3A signaling. (a) Representative images
of individual PTENWT melanoma cells stained with; MitoTracker Deep Red (red), phalloidin (green) and Hoechst (blue). Arrows highlight
peri-nuclear clustering of mitochondria. Scale bar, 50 μm. (b) Cells stained with MitoTracker Deep Red (250 nM) were imaged at high power
(63 × ; upper panel). Scale bar, 5 μm. Lower panel; zoomed-in images (150 × ) of mitochondria from red inset square as shown in upper panel
images. (c) Representative 3D images of Imaris (Bitplane AG, Zurich, Switzerland) analysis of M202 cells with example mitochondrial networks
highlighted in yellow. Cells were stained with the following markers: MitoTracker Deep Red (red), phalloidin (green) and Hoechst (blue). Scale
bar, 15 μm. (d) Quantiﬁed Imaris data for PTENWT melanoma cells. Numbers in each chart represent the percentage of mitochondria that range
in size from 0.1 to 10 μM2 for each treatment. *Po0.05 or **Po0.01.
Figure 3. PTENWT cells have reduced metabolism in response to WNT/β-catenin signaling. (a) Bioenergetic metrics were calculated from the
XFe96 extracellular ﬂux bioanalyzer OCR and ECAR traces (see Supplementary Figure 3 for example traces). Upper panel PTENWT A375 cells,
Lower panel PTENMut A2058 cells. Basal respiration was calculated from the OCR data at 26 min, subtracting the non-mitochondrial
respiration. ATP production was calculated by the change in OCR before and after injection of oligomycin. Maximal respiratory capacity was
calculated after injection of FCCP, as the maximum OCR reading subtracting non-mitochondrial respiration. Non-mitochondrial respiration
was calculated from the OCR data following injection of complex I and III inhibitors; antimycin A and rotenone, respectively. Basal ECAR was
calculated from the ECAR data at 26 min, by subtracting the non-glycolytic acidiﬁcation. Mean shown± s.d. *Po0.05 or **Po0.01 and
***Po0.001. (b) The shift in cellular energy phenotypes was calculated from basal OCR and basal ECAR readings for control and WNT3A
overexpressing PTENWT A375, and PTENMut A2058 cells. (c) Fold-change in CS activity normalized to total protein concentration. In parental
lines, readings were taken following 48 h of stimulation with carrier or 50 ng/ml rWNT3A. (d) Fold-change in lactate secretion normalized to
total protein concentration, using the same experimental conditions as described for c. For panels c and d, mean shown± s.d. *Po0.05 or
**Po0.01 and ***Po0.001.
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of mitochondrial morphology, as previously reviewed.48 Given the
metabolic-induced effects of WNT3A in melanoma cells (Figure 3),
we decided to investigate mitochondrial architecture in these cells
using the cell-permeant, MitoTracker mitochondrion-selective
probe (Invitrogen, Life Technologies Ltd, Paisley, UK). This led us
to the intriguing observation that in PTENWT melanoma cells in
response to WNT3A, the mitochondria amassed in dense peri-
nuclear clusters (Figure 4a), which was not apparent in the
WNT/β-catenin and melanoma metastasis
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PTENMut cells (Supplementary Figure 4a). Higher power images of
mitochondrial regions in PTENWT melanoma cells in response to
forced WNT3A signaling showed that the mitochondria appeared
to be elongated in shape compared with the control cells
(Figure 4b). To quantify this, we generated Z-stacks across the
depth of the cells, to provide 3D imaging of mitochondrial
morphology and used Imaris software (Bitplane AG, Zurich,
Switzerland) to measure the surface area of interconnected
structures (Figure 4c). This showed that in PTENWT cells there
was a signiﬁcant increase in mitochondrial sizes in response to
WNT3A signaling (Figure 4d), suggesting that the dense mito-
chondrial staining observed in the peri-nuclear region of these
cells (Figure 4a) is composed of larger mitochondrial networks.
Interestingly, we did not see this effect in PTENMut cells, where
there was no signiﬁcant effect of WNT3A on mitochondrial
networking (Supplementary Figure 4b). These results showed that
in PTENWT melanoma cells, WNT3A signaling remodels mitochon-
drial morphology, which does not occur in PTENMut cells.
WNT3A-mediated metabolic and mitochondrial effects
are β-catenin-dependent
Findings from our reporter assay experiments suggest that in
melanoma cells, WNT3A is signaling in a β-catenin-dependent
manner (Figures 1d and f). Given that this is consistent with
previous ﬁndings,15 we hypothesized that the novel metabolic
and mitochondrial effects we have noted in PTENWT melanoma
cells in response to WNT3A signaling, is dependent upon
β-catenin activity. We therefore examined the effects of transient
knockdown of β-catenin in PTENWT WNT3A overexpression
melanoma cells using small interfering RNA (siRNA) and found
efﬁcient reduction of CTNNB1 gene expression in response to
treatment (Figure 5a). To ensure this knockdown approach was
able to reduce β-catenin signaling, we also conﬁrmed that the
WNT/β-catenin target gene, AXIN2,49 was effectively reduced
(Supplementary Figure 5a).
Using this β-catenin knockdown approach, we began to
evaluate whether we could conﬁrm some of our previous ﬁndings
made using hyperactive WNT3A signaling, starting with cell
migration in the PTENWT melanoma cells. This showed that as
expected, reduced β-catenin expression led to increased migra-
tion of the PTENWT cells (Figure 5b). Furthermore, a reduction in
β-catenin expression could signiﬁcantly increase cellular metabo-
lism in the PTENWT melanoma cells as demonstrated by increased
CS activity (Figure 5c) and lactate secretion (Figure 5d), compared
with control siRNA-treated cells. In addition to its role in WNT/β-
catenin signaling, β-catenin also constitutes part of the cell–cell
adhesion adherens junction complex,50 which may also be
effected by knockdown in CTNNB1 expression. To rule out that
the metabolic and mitochondrial changes induced by β-catenin
knockdown may be due to a depletion of the adherens junction
pool, we used recombinant Dickkopf WNT signaling pathway
inhibitor-1 (rDKK1), which is a well-known secreted inhibitor of the
WNT/β-catenin signaling pathway.51 By forming a ternary complex
with LRP5/6 along with another receptor, Kremen, DKK1
stimulates the endocytic removal of LRP5/6 from the cell surface
thereby preventing WNT ligand-mediated stimulation of the WNT/
β-catenin pathway.52 We found that rDKK1 treatment of WNT3A-
stimulated A375 (PTENWT) melanoma cells not only inhibited WNT/
β-catenin signaling (Supplementary Figure 5b), but importantly
could also elevate WNT3A-mediated reduction in lactate secretion
in PTENWT melanoma cells (Figure 5e).
Next, we evaluated whether inhibition of β-catenin signaling
resulted in mitochondrial remodeling in the PTENWT melanoma
cells. Using the MitoTracker imaging and Imaris software analysis
(as previously shown in Figure 4 and Supplementary Figure 4c),
we found that rDKK1 blocked WNT3A-mediated increased
mitochondrial networking (Figure 5f) and that knockdown of
β-catenin led to fragmentation of the mitochondrial network
(Figure 5g), which resulted in a marked increase in the number of
mitochondria that ranged in size from 0.1 to 10 μM2, compared
with scrambled siRNA-treated cells (Figure 5h). Taken together,
these ﬁnding show that β-catenin signaling is essential for
mitochondrial remodeling induced by WNT3A (Figure 4), but also
for the WNT3A-mediated bioenergetic reprogramming of PTENWT
melanoma cells (Figure 3).
To investigate how β-catenin regulates these processes, we
assessed target proteins in the cells that bind β-catenin in the
absence and presence of the WNT3A ligand, using a proteomics
approach of immunoprecipitation followed by mass spectrometry.
We unbiasedly analyzed proteins with increased and decreased
binding to β-catenin in WNT3A PTENWT overexpression cells
compared with control cells. Immunoprecipitated proteins were
digested and the corresponding peptides were quantiﬁed using
label-free methods,53 a method that was demonstrated to be
highly reproducible (Supplementary Figure 5c). This immunopre-
cipitation mass spectrometry approach showed that in melanoma
cells, the majority of β-catenin-binding proteins compared
with the IgG control were involved in metabolic processes
(Figure 5i), but the composition of the metabolism proteins were
vastly altered upon WNT3A-mediated stabilization of β-catenin
(Supplementary Tables S3 and S4). For example, a number
of key glycolysis enzymes exhibit reduced binding to β-catenin
in the presence of WNT3A ligand stimulation (including
glyceraldehyde-3-phosphate dehydrogenase, lactate dehydrogen-
ase, phosphofructokinase-1 and glucose-6-phosphate isomerase;
Supplementary Table S4), which suggests that upon WNT/
β-catenin signaling in PTENWT melanoma cells, β-catenin no
longer binds to glycolysis enzymes, which may lead to metabolic
reprogramming events such as reduced glycolytic capacity.
This is supported by the ﬁnding that a representative number of
these metabolic enzymes do not alter upon rWNT3A treatment,
Figure 5. WNT3A-mediated effects in PTENWT melanoma cells are β-catenin dependent. (a)Western blot analysis of β-catenin expression levels
in A375 WNT3A overexpression cells following transfection with β-catenin siRNA or scrambled control siRNA for 72 h. α-tubulin served as the
loading control. (b) Fold-change in cell migration in A375 WNT3A overexpression cells treated with scrambled or β-catenin siRNA. (c) Fold-
change in CS activity in A375 WNT3A overexpression cells treated with scrambled or β-catenin siRNA. (d) Fold-change in lactate secretion from
A375 WNT3A overexpression cells treated with scrambled or β-catenin siRNA, normalized to total protein concentration. (e) Fold-change in
lactate secretion from PTENWT cells treated with rWNT3A (50 ng/ml)± rDKK1 (50 ng/ml) or carrier treatment, normalized to total protein
concentration. (f) Quantiﬁed Imaris data for A375 overexpression cells treated with rWNT3A (50 ng/ml)± rDKK1 (50 ng/ml) or carrier control.
Numbers in each chart represents the percentage of mitochondria that range in size from 0.1 to 10 μM2 for each treatment. For panels (b–f),
mean shown± s.d. *Po0.05, **Po0.01, ***Po0.001 and ****Po0.0001 (as compared with control). (g) A375 overexpression cells stained
with MitoTracker Green (10 nM; green) and counterstained with Hoechst (blue). siRNA treatment as described above and in main text.
Example images shown. Scale bar, 10 μm. (h) Quantiﬁed Imaris data for A375 overexpression cells transfected with β-catenin siRNA or a
scrambled control siRNA. Numbers in each chart represent the percentage of mitochondria that range in size from 0.1 to 10 μM2 for each
treatment. ****Po0.0001. (i) PANTHER analysis of proteins identiﬁed by MS-IP with increased (upper panel) and decreased (lower panel)
binding to β-catenin. See main text for experimental detail of the MS-IP approach used. (j) Western Blot for enzymes identiﬁed by MS-IP
analysis; LDHA, LDHB, PFKB. MFN1 was used as a positive control (see later text and Figure 7). Parental lines were stimulated with carrier or
50 ng/ml rWnt3a, 48 h before analysis.
WNT/β-catenin and melanoma metastasis
K Brown et al
9
Oncogene (2017), 1 – 18
suggesting that the observed decrease in β-catenin binding is
unlikely to result from the downregulation of total enzyme levels
(Figure 5j). Overall, these ﬁndings indicate that melanoma cells
expressing high levels of PTEN respond to WNT3A signaling with
metabolic reprogramming and mitochondrial remodeling, which
is dependent upon β-catenin activity.
WNT/β-catenin signaling does not alter mitochondrial numbers in
PTENWT melanoma cells, but can increase mitochondrial
membrane potential
In murine myoblasts, WNT3A/β-catenin signaling has previously been
shown to increase mitochondrial biogenesis,54 therefore it is
reasonable to presume that the mitochondrial effects noted
in PTENWT melanoma cells in response to hyperactive WNT/β-catenin
signaling (Figures 4 and 5), could be due to alterations in
mitochondrial numbers in these cells. To test this, we ﬁrst used
MitoTracker dye and quantitatively analyzed uptake in the PTENWT
melanoma cells using ﬂow cytometry as an indication of the total
amount of mitochondria in the cells, however, we did not detect a
difference in cells either treated with rWNT3A or overexpressing
WNT3A, compared with control-treated cells (Figure 6a). These results
suggest that the total number of mitochondria is not affected by
WNT/β-catenin signaling in PTENWT melanoma lines. To conﬁrm this,
we analyzed mitochondrial DNA copy number and found no increase
in response to hyperactive WNT3A signaling (Figure 6b). As expected
nor did we see an effect of WNT3A signaling on mitochondrial
Figure 6. WNT3A does not alter mitochondrial numbers in PTENWT melanoma cells, but does increase ΔΨm. (a) Flow cytometric analysis of
MitoTracker Green staining in PTENWT melanoma cells. Parental lines were stimulated with carrier or 50 ng/ml rWNT3A, 48 h before analysis.
(b) Total mitochondrial amount on A375 overexpression cells was monitored by analyzing mitochondrial DNA content normalized to nuclear
DNA using PCR, to provide a relative copy number (RCN) ratio. Mean shown± s.d. (c) JC-1 analysis of ΔΨm in PTENWT overexpression cells or
following stimulation with carrier control or rWNT3A (50 ng/ml) for 48 h. (d) Percentage change in JC-1 expression levels in gates R1 and R2 in
PTENWT overexpression cells or following stimulation with carrier control or rWNT3A (50 ng/ml) for 48 h. Mean shown± s.d. *Po0.05.
Figure 7. WNT/β-catenin signaling regulates mitochondrial dynamics machinery in PTENWT melanoma cells. (a) Western blot for mitochondrial
dynamic genes, MFN1, MFN2, OPA1 and DRP1 in total protein extracts and mitochondrial sub-fractions of A375 control and WNT3A
overexpression cells. E-cadherin and α-tubulin were used to judge the purity of the mitochondrial extraction, whereas Ponceau staining was
used to judge equal loading across all sample sets. (b) Western blot analysis of MFN1 expression in PTENWT melanoma cells stimulated with
carrier control or rWNT3A (50 ng/ml) for 48 h. Densitometry data for this blot are shown in Supplementary Figure 7a. (c) Western blot analysis
of MFN1 in A375 WNT3A overexpression cells treated with scrambled and β-catenin siRNA for 72 h. (d) Western blot analysis of MFN1
expression in A375 cells treated with scrambled and PTEN siRNA for 72 h followed by stimulation with carrier control or rWNT3A (50 ng/ml) for
48 h. (e) Quantiﬁed Imaris data of mitochondrial size in A375 cells transfected with PTEN siRNA or a scrambled control siRNA for 72 h before
stimulation with carrier control or rWNT3A (50 ng/ml) for 48 h. Numbers in each chart represents the percentage of mitochondria that
range in size from 0.1 to 10 μM2 for each treatment. *Po0.05 and ***Po0.001 (as compared with control). (f) Reverse transcription
(RT)–quantitative PCR (qPCR) for MFN1, MFN2, OPA1 and DNM1L (encoding for DRP1) transcripts in A375 control and WNT3A overexpression
cells. mRNA expression levels were normalized based on the expression of three housekeepers, YWHAZ, UBC and ACTB. (g) A375 control and
WNT3A overexpression cells were analyzed by western blot for Parkin and PINK1 expression. FL-PINK1 indicted by the 60 kDa band and the
cleaved isoform by the 50 kDa band. (h) A375 control and WNT3A overexpression cells were analyzed by western blot for autophagy markers
LC3 and p62 (left panel), and following treatment with β-catenin or scrambled siRNA (right panel). For all western blot panels, α-tubulin served
as the loading control. Graph shows the ratio of LC3I (18 kDa) to LC3II (16 kDa) in total protein and following treatment with β-catenin or
scrambled siRNA in A375 control and WNT3A overexpression cells (calculated from data shown). (i) Representative images of A375 cells
following stimulation with carrier control or rWnt3a (50 ng/ml) and Rapamycin (as a positive control103; 200 nM) or control for 48 h. Cells
stained with; MitoTracker Deep Red (red), LC3 (green) and Hoechst (blue). Scale bar, 50 μm. Graph shows the number of LC3 puncta, mean
shown± s.d. **Po0.01 and ****Po0.0001. (j) Reverse transcription (RT)–quantitative PCR (qPCR) for SQSTM1 (encoding p62) and AXIN2
transcripts in A375 cells following stimulation with carrier control or rWnt3a (50 ng/ml) for 48 h. mRNA expression levels were normalized
based on the expression of the housekeeper ACTB. ***Po0.001 and ****Po0.0001.
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content in PTENMut melanoma cells (Supplementary Figure 6a).
Taken together, these results show that WNT/β-catenin signaling
does not increase mitochondrial biogenesis in these cells and the
effects noted on increased mitochondrial networking in PTENWT
melanoma lines (Figures 4 and 5) are independent of changes in
total mitochondrial numbers.
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Despite not affecting total mitochondrial content, we did ﬁnd
that WNT3A was capable of altering the mitochondrial membrane
potential (ΔΨm) of PTENWT melanoma cells, using ﬂuorescent
probes (Figures 6c and d and Supplementary Figure 6b).
Speciﬁcally, WNT3A signaling was able to increase the population
of mitochondria exhibiting increased levels in ΔΨm compared
with control A375 cells, using both the ΔΨm-dependent JC-1
(Figures 6c and d) and TMRM (Supplementary Figure 6b)
ﬂuorescence indicators. Changes in ΔΨm are closely linked to
mitochondrial morphology, therefore these results suggest that
the increase in mitochondrial networking induced by WNT/β-
catenin signaling in PTENWT cells (Figures 4 and 5) could be
related to the increase in ΔΨm also noted.
Mitochondrial dynamics and mitophagy are regulated by WNT/β-
catenin signaling in PTENWT melanoma cells
Given that the WNT/β-catenin signaling pathway increased
mitochondrial networking in PTENWT melanoma cells (Figures 4
and 5), we hypothesized that the mitochondrial fusion and
ﬁssion mechanisms (the so-called mitochondrial dynamics
machinery) could be regulated to permit increased networks.
Mitochondria cycle through repetitive cycles of fusion and
ﬁssion that determines the architecture of the mitochondrial
network, to ultimately inﬂuence every aspect of mitochondrial
function (including intermediary metabolism), where these
processes are mediated by a number of GTPase pro-fusion
(Mitofusin-1 (MFN1), Mitofusin-2 (MFN2) and Optic atrophy-1
(OPA1)), and pro-ﬁssion (Dynamin-1-like protein (DRP1) and
Mitochondrial ﬁssion-1 (FIS1)) proteins.55 We tested whether
hyperactive WNT/β-catenin signaling was capable of regulating
expression of some of these mitochondrial dynamics proteins in
PTENWT melanoma cells and found that it increased expression
of pro-fusion proteins, whereas concomitantly reducing the
pro-ﬁssion, DRP1 levels (Figures 7a–c and Supplementary
Figure 7a). As increased expression of mitochondrial fusion
proteins MFN1, MFN2 and OPA1 would explain why mitochon-
drial networks are increased in PTENWT melanoma cells, we
veriﬁed their increased expression in response to WNT/β-catenin
signaling by immunoﬂuorescence (Supplementary Figure 7b)
and ﬂow cytometry (Supplementary Figure 7c) to further
corroborate our ﬁndings.
As we were unable to detect increased mitochondrial network-
ing in PTENMut melanoma cells in response to WNT/β-catenin
signaling (Supplementary Figure 4), we hypothesized that
reduction of PTEN in PTENWT cells (Supplementary Figure 7d)
would block WNT3A-mediated mitochondrial fusion. Indeed
transient knockdown of PTEN in PTENWT melanoma cells reduced
MFN1 expression, thereby antagonizing WNT3A-mediated increased
MFN1 expression and of note PTEN depletion appears to reduce
Figure 8. Working model portraying the effects of WNT/β-catenin signaling in PTENWT melanoma cells under nutrient starvation conditions. (a) In
the absence of a WNT ligand that signals via the WNT/β-catenin pathway, β-catenin is targeted by a destruction complex (comprising CK1, SCF,
GSK-3β, AXIN and APC) for proteasome-mediated degradation. Under nutrient starvation conditions (such as in large solid tumors), PTEN drives
increased autophagy. PTEN blocks PI3K-mediated activation of AKT (PKB), where AKT negatively regulates autophagy in response to mitogens
(in reality occurring through activation of mTOR; not shown). This triggers autophagy addiction in PTEN expressing tumors, which does not occur in
PTENMut melanomas. (b) In response to a WNT/β-catenin signaling ligand, the seven-transmembrane domain FZD receptors (blue/brown color in
schematic) and LRP5/6 receptor complex, results in activation of DVL, which in turn inactivates the destruction complex. Cytoplasmic β-catenin then
accumulates and is eventually translocated to the nucleus, where it interacts with transcription factor/lymphoid enhancer-binding element
transcription factors to activate/repress expression of WNT target genes including SQSTM1 (gene encoding p62), which is transcriptionally repressed
in response to β-catenin signaling. p62 is an autophagy adaptor that facilitates the autophagic degradation of ubiquitinated protein aggregates. We
propose that inhibition of autophagy by WNT/β-catenin signaling in autophagy addicted cancer cells, inhibits mitophagy leading to nonselective
mitochondrial fusion. This results in a highly networked, yet dysfunction mitochondrial population with signiﬁcantly reduced cellular metabolic
capacity, which negatively affects tumor cell behavior such as motility and metastasis.
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MFN1 expression in these cells (Figure 7d). Crucially PTEN
knockdown also antagonized increased mitochondrial networking
in response to WNT/β-catenin signaling, in PTENWT melanoma
cells (Figure 7e). We were unable to identify altered mRNA
expression levels of mitochondrial dynamics genes in PTENWT cells
in response to hyperactive WNT/β-catenin signaling (Figure 7f),
suggesting that rather than being transcriptionally regulated by
β-catenin signaling, expression levels of these proteins are
regulated in a post-transcriptional manner.
Parkin is a RING-between-RING-type E3 ubiquitin ligase involved
in the mitophagy quality control pathway to remove damaged
mitochondria, which ubiquitinates multiple outer mitochondrial
membrane (OMM) proteins (marking them for degradation)
including MFNs56 and is targeted to depolarized mitochondria
by PTEN-induced putative kinase-1 (PINK1). We investigated
PINK1-Parkin accumulation in PTENWT melanoma cells in response
to WNT/β-catenin signaling to determine whether impairment of
either could lead to increased levels of MFN proteins and found
that while differences in Parkin levels were modest (slightly
increased in response to WNT3A signaling; Figure 7g and
Supplementary Figure 7e; which ﬁts with the recent ﬁnding that
WNT3A increases endogenous Parkin in glioblastoma cells57), we
did detected a marked difference in PINK1 expression (Figure 7g).
PINK1 undergoes voltage-dependent proteolysis in healthy
mitochondria, but is stabilized in a full-length (FL) form on the
OMM of damaged mitochondria,58 where we found that WNT3A
increased FL-PINK1 expression (Figure 7g), suggesting that
PTENWT melanoma cells harbor defective mitochondria in
response to WNT/β-catenin signaling that are tagged for selective
autophagy (mitophagy). Importantly, the uncoupler, FCCP (which
dissipates ΔΨm), also stabilizes FL-PINK1 in PTENWT melanoma
cells, demonstrating that these cells are capable of proteolytic
cleaving of PINK1 (Supplementary Figure 7f). Further investiga-
tions demonstrated that autophagy markers are markedly
reduced in PTENWT melanoma cells in response to hyperactive
WNT3A signaling (Figure 7h), but not in PTENMut cells
(Supplementary Figure 7g) suggesting that autophagy (and thus
the mitophagy process), is impaired in PTENWT melanoma cells in
response to WNT/β-catenin signaling. This has been further
corroborated by analyzing LC3 punctae staining in the presence
of an autophagy inducer and found that WNT3A can signiﬁcantly
reduce autophagosome function in PTENWT melanoma cells
(Figure 7i). WNT/β-catenin signaling has previously been found
to be a negative regulator of autophagy, by repressing p62
(encoded by SQSTM1) expression, which is a protein that targets
cargos for autophagy.59 Importantly, we also detect repression of
SQSTM1 expression in PTENWT melanoma cells following treatment
with rWNT3A (Figure 7j).
Overall, our ﬁndings show that cells harboring deletion
mutations of PTEN increase their invasive capacity in response
to WNT/β-catenin signaling, whereas PTENWT cells exhibit a
signiﬁcant reduction in invasion and metastasis (Figure 2), the
latter of which is accompanied by a marked reduction in cellular
metabolism (Figure 3) and mitochondrial remodeling (Figure 4).
This remodeling involves the formation of fused networks of
mitochondria, which is achieved by increased expression of
mitochondrial fusion and reduced ﬁssion proteins, resulting from
reduced mitophagy (Figure 7). We propose a model whereby
WNT/β-catenin signaling in PTENWT melanoma cells leads to the
accumulation of MFNs on damaged mitochondria, directing them
toward reengagement in fusion events (nonselective mitochon-
drial fusion) due to defective mitophagy (Figure 8). This will likely
lead to the accumulation of damaged mitochondria through
nonselective fusion with limited ﬁssion events, leading to a static
hyperfused mitochondrial state that has previously been asso-
ciated with reduced mitochondrial respiration,60 a situation that
could ultimately affect cellular activities such as motility.
DISCUSSION
In melanoma, the role of the WNT/β-catenin pathway is
controversial,15,18,22,42,61–63 where differing tumor mutational
status may account for these discrepancies. Indeed, β-catenin
signaling has been shown to increase or repress melanoma cell
invasion depending on the cell line tested.18,42 Here we provide
evidence that a reduction in PTEN expression in melanoma cells
markedly alters their phenotypic response to WNT/β-catenin
signaling by reprogramming distinct metabolic signatures, which
is underpinned by changes in mitochondrial activity in PTENWT,
but not in PTENMut cells.
PTEN can be frequently lost in melanoma,64 where it functions
as a tumor suppressor to negatively regulate PI3K-AKT signaling
through the dephosphorylation of the plasma membrane bound
phospholipid, phosphatidylinositol-3,4,5-trisphosphate, which
functions downstream of PI3K to activate AKT. Increased AKT
activity promotes glycolysis through multiple mechanisms,
including upregulated glucose transport65,66 and increased
hexokinase activity.67,68 Conversely, PTEN can promote oxidative
phosphorylation and reduce glycolysis,69 suggesting that tumor
cells harboring loss of or reduced PTEN expression will have
markedly differing metabolic proﬁles to cells without PTEN loss.
We have previously reviewed the critical role WNT signaling has in
cancer cell metabolism,25 so our current ﬁnding that WNT/β-
catenin signaling imparts altered metabolic proﬁles in melanoma
cells dependent on PTEN expression levels, demonstrates that
cross-talk between the PI3K-AKT and WNT/β-catenin pathways
exists to induce metabolic reprogramming in tumor cells.
Hyper-activation of the mitogen-activated protein kinase
signaling pathway through constitutively activating mutations
in BRAF or NRAS causes oncogene-induced senescence in
melanocytes,70,71 which can be circumvented by the further
acquisition of genes that allow for bypass of the senescence
program, including PTEN and β-catenin;71,72 albeit NRAS and PTEN
mutations have been suggested to be mutually exclusive as
oncogenic RAS can activate the PI3K-AKT pathway in melanoma.73
This is unlike activating mutations in BRAF, which are frequently
found co-occurring with loss of PTEN in melanoma.74 Similar to
PTEN loss, activation of β-catenin also occurs in melanoma, where
nuclear β-catenin has been reported in a third to two-thirds of all
tumors,75,76 suggesting it may have a role in tumor progression
(at least in some patients). Our ﬁndings show that the effects of
β-catenin signaling in melanoma cells differs depending on PTEN
expression; in the absence of PTEN loss, cellular bioenergetics is
compromised by β-catenin and tumor invasion/metastasis
reduced, whereas cells exhibiting reduced expression of PTEN
have increased invasion in response to β-catenin signaling, which
does not appear to be due to a deﬁnable metabolic reprogram-
ming event in these cells, suggesting the pro-invasive effects of
WNT/β-catenin signaling are potentially independent of metabolic
reprogramming in this particular context. Our ﬁndings are
supported by a transgenic mouse model, where stabilized
β-catenin combined with PTEN loss and activating BRAFV600E
mutation in cells of melanocytic origin, resulted in increased
metastasis.22 β-Catenin stabilization in this model was recently
shown to block T-cell recruitment to the tumors, providing
resistance to immunotherapies and showing that WNT/β-catenin
signaling can promote progression of melanoma through a variety
of mechanisms in this speciﬁc mutational background,77 where
(unlike in melanoma cells expressing PTEN) maintenance of high
metabolic activity would be essential for WNT/β-catenin signaling
to promote tumor progression in this context.
PTEN antagonizes nuclear accumulation of β-catenin,78,79
suggesting that in PTENWT melanoma cells, WNT/β-catenin
signaling may be restricted compared with the PTENMut cells,
which may explain the phenotypic differences observed between
the two cell types. However, the WNT/β-catenin pathway is not
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blocked in PTENWT melanoma cells and can still be strongly
activated by exogenous WNT treatment (Figures 1c and d),
demonstrating that the pathway is at least partially functional in
the cell lines tested here. Another possible explanation for the
differing effects of WNT/β-catenin signaling on cell migration and
invasion of PTENMut and PTENWT melanoma cells, could be a
difference in expression of the Microphthalmia-associated tran-
scription factor (MITF), which is a target of WNT/β-catenin
signaling and can regulate aggressive behavior in melanoma
cells.80,81 However, we were unable to identify differences in
expression of MITF between the PTENMut and PTENWT melanoma
cells (data not shown) and inhibition of cell migration by β-catenin
has only been shown to be partially dependent on MITF in
melanocyte lineage cells,61 suggesting that differing MITF expres-
sion levels are unlikely to account for the difference in cell
migration and invasion noted here for the PTENMut and PTENWT
melanoma cells in response to WNT/β-catenin signaling. Rather,
we suggest that the differences in cell motility identiﬁed between
these two cells types are due to a fundamental change induced
by the WNT/β-catenin pathway on the metabolic status of the
melanoma cells.
In melanoma, mitochondria remain functional82,83 and we have
discovered distinct mitochondrial activity between PTENWT and
PTENMut cells in response to WNT/β-catenin signaling. Speciﬁcally,
we found that in PTENWT melanoma cells, WNT/β-catenin
signaling increases mitochondrial networking by upregulating
expression of mitochondrial fusion proteins and concomitant
downregulation of mitochondrial ﬁssion machinery, indicating
that this pathway is an important regulator of mitochondrial
dynamics at least in a subset of melanoma cells. Interestingly, this
WNT pathway is not the only one that can control mitochondrial
morphology, as the WNT5A/Ca2+ signaling pathway has also been
found to modulate mitochondrial dynamics in normal cells by
promoting ﬁssion84–86 (at least in part through DRP1 activation84).
However, in these same cells, the WNT/β-catenin pathway was
unable to regulate mitochondrial aggregation, failing to alter
mitochondrial morphology nor antagonize WNT/β-catenin-inde-
pendent-mediated mitochondrial ﬁssion,85,86 highlighting the
context-dependent nature of the WNT signaling network on
mitochondrial dynamics. It is tempting to speculate that the
effects of the WNT/β-catenin pathway in regulating mitochondrial
dynamics in PTENWT melanoma cells, may highlight a potentially
novel tumor-speciﬁc role of this pathway in certain cancer
contexts. It remains to be determined which additional tumor
types may also be affected, however, other cancer cells that
exhibit augmented metabolic proﬁles in response to WNT/β-
catenin signaling, such as colorectal cancer,27 represent a logical
extension to further such studies.
PINK1-Parkin signaling represents a mitochondrial quality
control pathway that is able to tag defective mitochondria for
selective degradation by the autophagosomal machinery, where
the current model states that PINK1 is selectively stabilized on the
OMM of defective mitochondria, facilitating Parkin recruitment to
poly-ubiqutinated OMM proteins (including MFN1 and MFN2) and
isolate defective mitochondria in the autophagosome.56,87–92 In
this model, PINK1 is turned over by proteolysis in well-coupled
mitochondria, but when the ΔΨm drops, FL-PINK1 is stabilized on
the OMM, allowing for selective accumulation on impaired
mitochondria and marking these organelles for degradation.93
However, our data contrast with this current model where we
detected high expression of FL-PINK1 in response to WNT/β-
catenin signaling in PTENWT cells, despite a concomitant increase
in ΔΨm (which may be effected by altered mitochondrial
dynamics). Interestingly there are a couple of alternative, ΔΨm-
independent mechanisms can also result in FL-PINK1 accumula-
tion, which include overwhelming of the mitochondrial import
channels with excess PINK1 and preventing PINK1 cleavage by
reducing mitochondrial protease activity.93,94 One of these or an
alternative mechanism could be responsible for the increased FL-
PINK1 levels observed in PTENWT melanoma cells in response to
WNT/β-catenin signaling. Mitophagy is deﬁned as the degradation
of mitochondria through the macroautophagic pathway, thus
defects in the autophagic machinery inhibit mitophagy. We found
an increase in p62 protein following β-catenin knockdown and
β-catenin-mediated repression of the SQSTM1 transcript, as well as
increased autophagosome numbers (Figure 7), highlighting p62
regulation as a WNT/β-catenin-mediated mitophagy regulation
mechanism in PTENWT melanoma cells (Figure 8). However, we
cannot rule out that another autophagy regulator is also involved,
given that p62 accumulation itself is also a marker of autophagy.95
Interestingly, DKK3 (a WNT/β-catenin signaling regulator) was
recently found to be a marker of autophagy in melanoma,
suggesting that inhibition of WNT/β-catenin signaling could
increase autophagy in melanoma cells.96
Our model (Figure 8) can also explain why this mitophagy-
dependent phenotype is not observed in PTENMut melanoma cells:
It has long been known that PTEN can increase autophagy by
inhibiting AKT activity97 (and independently of AKT-mTOR
activity98), and that loss of AKT in PTEN-null cancer cells induces
autophagy,99 suggesting that tumor cells with reduced PTEN
expression will have reduced autophagy in general. Indeed our
data support this where the PTENMut A2058 cells exhibit low basal
autophagy as seen by low expression of the autophagy marker,
LC3II, which does not alter markedly in response to WNT3A
signaling (Supplementary Figure 7g). PTENWT cancer cells, how-
ever, are autophagy proﬁcient, conferring a major mechanism of
stress tolerance in these cells (such as during nutrient deprivation)
for tumor cell survival, which makes them particularly susceptible
to autophagy inhibition (such as that induced by WNT/β-catenin
signaling).
Small-molecule WNT antagonists have been developed for
cancer treatment, however, because the role of the WNT/β-catenin
pathway is controversial, it is difﬁcult to predict how such drugs
could be implemented in the treatment of melanoma. Here we
show that the effects of the WNT/β-catenin pathway differ vastly
in melanoma depending on PTEN expression levels; when PTEN
levels are high, β-catenin signaling reduces metastasis, inhibits
mitophagy and reduces the bioenergetic status of the cells (none
of this occurs in melanoma cells with depleted PTEN levels).
Genomic subtyping in cancer is needed for the implementation of
molecular therapies and recent TCGA stratiﬁcation of cutaneous
melanomas provides a potential guideline for therapeutic
decisions.100 Our results suggest that PTEN expression level could




Details of all cells, culture conditions, reagents and statistical analyses used
are provided in the Supplementary Methods section of the Supplementary
Material, along with western blot details and all additional methodology
used to generate the data presented in the Supplementary Figures.
Melanoma cells were plated in 24-well plates and transiently trans-
fected with 150 ng of either Super8TOPFlash or Super8FOPFlash reporter
constructs101 for 6 h in media without serum or antibiotics. A Renilla
luciferase expression plasmid was co-transfected for normalization of
transfection efﬁciency. Transfected cells were then stimulated for 24 h with
either rWNT3A (50 ng/ml) or carrier control. Cell extracts were assayed for
luciferase activity using the dual luciferase kit (Promega UK, Southampton,
UK), according to the manufacturer’s instructions. Renilla-normalized
TOPFlash results were then normalized to FOPFlash expression and the
data presented as actual luminescence units.
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Apoptosis assay
Apo-TRACE Apoptotic Cell Staining Kit (Sigma-Aldrich, Dorset, UK) was
used according to the manufacturer’s instructions. Brieﬂy, cells were serum
starved for 48 h, washed in phosphate-buffered saline and Apo-TRACE
added at 75 μg/ml for 1 h in the dark. Cell lysates were read at ex 328 nm,
em 563 nm on a POLARstar Optima microplate reader (BMG Labtech,
Aylesbury, UK). Results were normalized to total protein concentration, as
assessed by BCA assay (Fisher Scientiﬁc UK Ltd, Loughborough, UK).
In vitro wound assay
This was done as previously described.26 Brieﬂy, a wound was scratched
across a conﬂuent monolayer of melanoma cells and the wells rinsed with
fresh media to remove ﬂoating cells. Images were taken of the scratched
area at × 10 magniﬁcation, where the wound-healing process was
monitored at 24 and 48 h in the same location. Images were analyzed
using Image J software (NIH, Bethesda, MD, USA) to measure the open area
of cells and the data presented as fold-change in wound conﬂuence over
the control.
Transwell assay
Melanoma cells were either stimulated in serum-free media or serum-
starved for 48 h before the assay (as indicated for each experiment),
resuspended in serum-free medium and added to the upper chambers of
8.0 μm pore inserts (Corning, Corning Optical Communications, Flintshire,
UK) coated with Matrigel (BD Biosciences, Oxford, UK). Growth media were
added to the lower chamber and the cells incubated for 48 h. Migrating
cells were quantiﬁed after crystal violet staining. Each experiment was
performed in triplicate. The insert was then removed and the number of
invaded cells were analyzed as previously described.36
Mouse xenograft experiments
Low passage, lentiviral transduced WNT3A overexpression or control
cancer cells were suspended in phosphate-buffered saline at low passage.
10 × 105/ml cells were injected into 11-week-old, male NOD scid gamma
(NSG) mice through the tail vein using a 26G needle. Six mice were
injected per group (as determined by G*Power3 analytical software102) and
experiments performed in a blinded manner to ensure randomization of
the approach. Lungs were harvested 4 weeks post injection and ﬁxed with
10% neutral-buffered formalin (Fisher Scientiﬁc UK Ltd). All animal studies
were performed using Institutional Animal Care and Use Committee
protocols, as approved by a review board at the University of Washington.
Measurements of OCR and ECAR
OCR and ECAR were measured using the XFe96 ﬂux analyzer (Seahorse
Bioscience, Agilent Technologies LDA UK Ltd, Stockport, UK) and the XF
Cell Mito Stress Test kit (Seahorse Bioscience, Agilent Technologies LDA UK
Ltd), according to the manufacturer’s instructions. In all, 8x104 cells were
seeded onto poly-D-lysine-coated XF microplates. Brieﬂy, metabolic ﬂux
measurements were assessed under basal conditions and in response to
the ATP synthase inhibitor, oligomycin (2.5 μM), the electron transport
chain (ETC) accelerator, FCCP (1 μM), and ﬁnally the ETC complex 1 and 3
inhibitors, antimycin A and rotenone (2.5 μM), respectively. Data were
analyzed using the XF software (Seahorse Bioscience, Agilent Technologies
LDA UK Ltd).
CS activity assay
The CS Assay Kit (Sigma-Aldrich) was used according to the manufacturer’s
instructions. Cells were seeded and stimulated for 48 h before analysis and
results normalized to total protein concentration for each sample.
Lactate production assay
The Lactate Assay Kit (BioVision Inc., Milpitas, CA, USA) was used according
to the manufacturer’s instructions and experiments conducted as
previously described.26 Melanoma cells were seeded and stimulated or
not (as indicated for each experiment), 48 h before the analysis.
Immunoﬂuorescent and mitochondrial staining
Cells were grown and stimulated on 18-mm sterile coverslips for 48 h.
MitoTracker stains (Invitrogen, Life Technologies Ltd; 250 nM) were diluted
in phenol-red-free media and incubated with the cells for 15 min at 37 °C.
The stain was then removed and replaced with 1 ml phenol-red-free media
and incubated at 37 °C for 10 min. Following staining, cells were ﬁxed
using 5% paraformaldehyde for 10 min, permeabilized using 0.5% Triton
X-100 for 5 min and then counterstained with Phalloidin 488 (0.25 units)
and Hoechst 33342 (10 nM).
For immunostaining, MFN1, MFN2, OPA1 and LC3 antibodies were
incubated with ﬁxed/permeabilized cells before detection using ﬂuores-
cent secondary antibodies (5 μg/ml), and counterstained with Hoechst
33342. After washing, cells were mounted with Vectashield mounting
medium (Vector Laboratories Ltd, Peterborough, UK) and analyzed (as for
the MitoTracker stained cells) by LSM 510 (Carl Zeiss Ltd, Cambridge, UK) to
capture Z-stack images at optimum slice depths for each sample. Gain
settings and exposure time were kept constant between samples. For
Imaris (Bitplane AG) analysis, sampling was carried out using 3D images to
calculate surface area staining by setting the background threshold to
0.5 μm. The area in deﬁned size ranges was then calculated by Imaris
software as a percentage of the total.
Reverse transcription and quantitative PCR
The Human Mitochondrial to Nuclear DNA Ratio Kit (NovaQUANT, EMD
Millipore, Watford, UK) was used according to the manufacturer’s protocol
for whole-cell lysis. In all, 50 cells per well in DNase/RNase-free water were
used with a 2X Fast SYBR green mastermix. For reverse transcription–
quantitative PCR, RNA was puriﬁed using the GeneJet RNA puriﬁcation kit
(Fisher Scientiﬁc UK Ltd.) following the manufacturer’s protocol. In total,
2 μg of complementary DNA was synthesized using RevertAid M-MuLV
Reverse Transcriptase (Fermentas, Fisher Scientiﬁc UK Ltd) and diluted to
100 ng/ml, followed by quantiﬁcation using SYBR green reagent (Fermen-
tas, Fisher Scientiﬁc UK Ltd) and a LightCycler 480 system (Roche, Welwyn
Garden City, UK). YWHAZ, UBC and ACTB were used as reference genes for
relative quantiﬁcation of the transcripts under investigation. All oligos used
for quantitative PCR are shown in Supplementary Table S5.
Immunoprecipitation mass spectrometry
For sample preparation, non-glycoslyated β-catenin was removed using
conA beads (BioWorld, Dublin, OH, USA). Samples were pre-cleared with
rabbit IgG before incubation with β-catenin-coated Dynabeads G (Novex,
Fisher Scientiﬁc UK Ltd). Immunoprecipitated proteins were solubilized in
1 M urea, 50 mM ammonium bicarbonate, pH 7.8, and heated to 50 °C for
20 min. Proteins were reduced with 2 mM DTT, alkylated with 15 mM
iodoacetamide and digested overnight with a 1:50 ratio of trypsin to total
protein. The resulting peptides were desalted on Waters Sep-Pak C18
cartridges (Waters, MA, USA). Peptides were measured by nano-LC-MS/MS
on a Thermo Scientiﬁc Q Exactive (QE). Peptides were separated online by
reverse-phase chromatography using heated 50 °C 30 cm C18 columns
(75 mm ID packed with Magic C18 AQ 3 μM /100 Α beads) in a 180 min
gradient (1% to 45% acetonitrile with 0.1% formic acid) and separated at
250 nl/min. The QE was operated in data-dependent mode with the
following settings: 70 000 resolution, 400–1600 m/z full scan, Top 10, and
an 1.8 m/z isolation window. Identiﬁcation and label-free quantiﬁcation
of peptides was done with MaxQuant 1.5 (Max Planck Institute of
Biochemistry, Martinsried, Germany), using a 1% false discovery rate
against the human Swiss-Prot/TrEMB (Swiss Institute of Bioinformatics,
Geneva, Switzerland) database. Three replicates per condition were
analyzed. Peptides were searched using a 5 p.p.m. mass error and a
match between run window of 2 min. Proteins that were signiﬁcantly
regulated between conditions were identiﬁed using a permutation-based
t-test (S1, false discovery rate 5%) in Perseus 1.4.1.3. Gene ontology (GO)-
terms were analyzed using Protein ANalysis THrough Evolutionary
Relationships (PANTHER) 9.0 (http://pantherdb.org).
Membrane potential measurements
Mitochondrial membrane potential measurements were made using ﬂow
cytometry protocols. Cells were grown and stimulated for 48 h before
incubation with JC-1 (eBioscience Ltd, Altrincham, UK) stain (2 μM) or
TMRM (Fisher Scientiﬁc UK Ltd; 20 μM) for 2 h. All samples were diluted in
phenol-red-free media. The stain was removed and replaced with 1 ml
phenol-red-free media and incubated at 37 °C for 10 min before
re-suspension in FACS buffer (phosphate-buffered saline+0.5% fetal calf
serum) and analysis on the Accuri C6 ﬂow cytometer (BD Biosciences).
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